Novartis AG
NVS
$155.33
-$0.81-0.52%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.23% | -12.48% | -14.51% | 23.17% | 24.49% |
| Total Depreciation and Amortization | 3.45% | 3.39% | 0.86% | 8.35% | 3.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.54% | -56.94% | 106.88% | -71.20% | 130.91% |
| Change in Net Operating Assets | -111.66% | 47.43% | -794.90% | 29.13% | 426.00% |
| Cash from Operations | -11.73% | 0.85% | -46.01% | 4.53% | 36.70% |
| Capital Expenditure | 3.02% | -36.22% | -9.14% | -10.28% | -27.31% |
| Sale of Property, Plant, and Equipment | 2,500.00% | -50.00% | -97.87% | 0.00% | -97.30% |
| Cash Acquisitions | -64.84% | -- | -172.07% | -60.34% | 49.47% |
| Divestitures | 663.64% | 50.00% | -105.49% | -1,014.29% | 57.69% |
| Other Investing Activities | 45.80% | 12.11% | 85.49% | -11,566.67% | -171.04% |
| Cash from Investing | -38.43% | -3,656.36% | 30.63% | -129.95% | 30.06% |
| Total Debt Issued | 157.65% | 1,998.02% | 21,458.33% | -96.32% | -72.06% |
| Total Debt Repaid | 87.00% | 91.47% | -2,147.56% | 44.31% | 69.71% |
| Issuance of Common Stock | -30.00% | -- | -- | -60.00% | -20.00% |
| Repurchase of Common Stock | 55.82% | 30.96% | 46.42% | 19.34% | -67.95% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -15.53% | -16.20% | -- | -- | -2.81% |
| Other Financing Activities | 68.84% | 239.13% | 3.13% | 151.16% | -760.00% |
| Cash from Financing | 61.25% | 141.87% | 156.17% | -630.10% | -62.91% |
| Foreign Exchange rate Adjustments | -104.71% | -142.78% | 111.46% | -112.50% | 1,223.53% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 280.24% | -3.76% | 187.40% | -49.18% | 73.82% |